What are the definition, etiology, classification, pathophysiology, clinical features, complications, diagnostic work‑up, and management recommendations for hypertension according to JNC 2?

Hypertension: Comprehensive Overview

Definition

Hypertension is defined as persistently elevated blood pressure ≥140/90 mm Hg based on JNC 7 criteria, though the question asks about JNC 2 which is outdated. The most relevant modern definition from JNC 7 (2003) classifies hypertension as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg 1, 2. Blood pressure is a continuous cardiovascular risk variable, with risk doubling for every 20/10 mm Hg increment starting from 115/75 mm Hg 1, 2.

Blood Pressure Classification (JNC 7)

• Normal: <120/80 mm Hg
• Prehypertension: 120-139/80-89 mm Hg (identifies individuals at high risk requiring lifestyle intervention)
• Stage 1 Hypertension: 140-159/90-99 mm Hg
• Stage 2 Hypertension: ≥160/100 mm Hg 1, 2

Note: JNC 2 is from the 1980s and is obsolete. Current practice follows JNC 7 (2003) or more recent guidelines like the 2020 VA/DoD 3 or 2025 AHA/ACC 4.

Etiology

Primary (Essential) Hypertension (90-95% of cases)

The etiology involves complex interactions between genetic predisposition, environmental factors, and pathophysiological mechanisms 5:

• Genetic factors: Family history of premature cardiovascular disease (age <55 in men, <65 in women) 6
• Environmental factors:
  • Excessive sodium intake (>2300 mg/day)
  • Obesity (BMI >24.9 kg/m²)
  • Physical inactivity
  • Excessive alcohol consumption (>14 drinks/week in men, >9 in women) 6
  • Chronic stress 6
• Age-related: Risk increases significantly after age 55; >75% of those in their eighth decade have hypertension 3

Secondary Hypertension (5-10% of cases)

Investigate when clinical features suggest:

• Renal disease: Chronic kidney disease, renovascular disease
• Endocrine disorders: Primary aldosteronism, pheochromocytoma, Cushing's syndrome, thyroid disorders
• Vascular: Coarctation of aorta
• Medications: NSAIDs, oral contraceptives, corticosteroids, sympathomimetics 6

Pathophysiology

Hypertension develops through multiple interconnected mechanisms that create a self-perpetuating cycle of vascular damage 5:

Key Pathophysiological Mechanisms

1. Renin-Angiotensin-Aldosterone System (RAAS) Activation

   • Increased angiotensin II causes vasoconstriction and sodium retention
   • Aldosterone promotes sodium and water retention, increasing blood volume
   • Leads to increased peripheral vascular resistance

2. Sympathetic Nervous System Overactivity

   • Increased catecholamine release
   • Enhanced cardiac output and vasoconstriction
   • Contributes to RAAS activation

3. Endothelial Dysfunction

   • Reduced nitric oxide bioavailability
   • Impaired vasodilation
   • Increased oxidative stress
   • Promotes inflammation and thrombosis

4. Vascular Remodeling

   • Arterial wall thickening (medial hypertrophy)
   • Increased arterial stiffness
   • Reduced vascular compliance
   • Elevated systolic pressure with aging

5. Sodium and Volume Dysregulation

   • Impaired renal sodium excretion
   • Increased intravascular volume
   • Enhanced pressure natriuresis threshold 5

Clinical Features

Hypertension is typically asymptomatic, earning it the designation "silent killer"—this asymptomatic nature leads to delayed diagnosis and poor treatment adherence 3.

Symptoms (Usually Only with Severe Hypertension or Complications)

• Headache (typically occipital, morning)
• Dizziness
• Blurred vision
• Epistaxis
• Chest pain
• Dyspnea

Hypertensive Emergency/Urgency Features

• Severe BP elevation (typically >180/120 mm Hg)
• Emergency (requires immediate treatment): Acute target organ damage
  • Hypertensive encephalopathy
  • Acute stroke
  • Acute myocardial infarction
  • Acute pulmonary edema
  • Acute kidney injury
  • Retinal hemorrhages/papilledema 6

Physical Examination Findings

• Elevated BP on repeated measurements
• Retinal changes (arteriovenous nicking, hemorrhages, exudates, papilledema)
• Cardiac: Left ventricular heave, S4 gallop
• Vascular: Diminished peripheral pulses, abdominal bruits (renovascular disease)
• Endocrine stigmata suggesting secondary causes

Complications

Uncontrolled hypertension damages multiple organ systems through sustained pressure-related injury and accelerated atherosclerosis 3, 1:

Cardiovascular

• Coronary artery disease and myocardial infarction
• Heart failure (both reduced and preserved ejection fraction)
• Left ventricular hypertrophy (independent risk factor for adverse outcomes)
• Atrial fibrillation
• Aortic dissection

Cerebrovascular

• Ischemic stroke (most common)
• Hemorrhagic stroke
• Transient ischemic attacks
• Vascular dementia

Renal

• Chronic kidney disease
• End-stage renal disease (particularly in African Americans) 3
• Proteinuria

Vascular

• Peripheral arterial disease
• Aortic aneurysm

Ophthalmologic

• Hypertensive retinopathy
• Vision loss

Diagnosis

Blood Pressure Measurement Technique

Proper BP measurement is critical—improper technique is a major source of misdiagnosis 6:

1. Patient preparation:

   • Seated quietly for 5 minutes
   • Feet flat on floor, back supported
   • Arm at heart level
   • Empty bladder
   • No caffeine, exercise, or smoking 30 minutes prior

2. Measurement:

   • Use validated automated device or manual sphygmomanometer
   • Appropriate cuff size (bladder encircles 80% of arm)
   • Take ≥2 readings, discard first, average remaining 6
   • Measure in both arms initially (use higher reading arm for future measurements)

Diagnostic Criteria

For patients WITHOUT target organ damage, diabetes, or CKD:

• Immediate diagnosis if BP ≥180/110 mm Hg at visit 2 6
• For BP 140-179/90-109 mm Hg: Requires confirmation over multiple visits
  • Office measurements: Average ≥140/90 mm Hg over 3-5 visits 6
  • OR Home BP monitoring: Average ≥135/85 mm Hg 6
  • OR 24-hour ambulatory BP: Mean ≥130/80 mm Hg 6

For patients WITH target organ damage, diabetes, or CKD (GFR <60):

• Can diagnose at visit 2 if BP ≥140/90 mm Hg 6

White Coat Hypertension

• Office BP ≥140/90 mm Hg
• Home BP <135/85 mm Hg AND 24-hour ambulatory BP <130/80 mm Hg 6

Investigation

Initial Laboratory Evaluation

All hypertensive patients require baseline assessment of target organ damage and cardiovascular risk 6, 1:

• Urinalysis: Proteinuria, hematuria
• Serum creatinine and eGFR: Assess renal function
• Electrolytes: Sodium, potassium (hypokalemia suggests aldosteronism)
• Fasting glucose or HbA1c: Screen for diabetes
• Lipid profile: Assess cardiovascular risk
• ECG: Left ventricular hypertrophy, ischemia, arrhythmias
• Urine albumin-to-creatinine ratio (ACR): Microalbuminuria (>30 mg/mmol) 7, 6

Additional Testing for Secondary Hypertension (When Indicated)

• Renovascular disease: Renal artery duplex ultrasound, CT/MR angiography
• Primary aldosteronism: Aldosterone-to-renin ratio
• Pheochromocytoma: 24-hour urine metanephrines or plasma metanephrines
• Cushing's syndrome: 24-hour urine cortisol, dexamethasone suppression test
• Thyroid disease: TSH

Cardiovascular Risk Stratification

Assess for additional risk factors that influence treatment decisions 6, 1:

Non-modifiable:

• Age ≥55 years
• Male sex
• Family history of premature CVD

Modifiable:

• Smoking
• Dyslipidemia
• Diabetes mellitus
• Obesity
• Physical inactivity

Target organ damage:

• Left ventricular hypertrophy
• Chronic kidney disease
• Retinopathy
• Peripheral arterial disease

Management

Lifestyle Modifications (ALL Patients)

Lifestyle interventions are mandatory for all hypertensive and prehypertensive patients—they can reduce BP by 5-20 mm Hg 6, 1, 2:

1. DASH Diet (Dietary Approaches to Stop Hypertension) 6:

   • Emphasize fruits (4-5 servings/day), vegetables (4-5 servings/day)
   • Low-fat dairy (2-3 servings/day)
   • Whole grains (7-8 servings/day)
   • Lean meats, poultry, fish (≤2 servings/day)
   • Nuts, seeds, legumes (4-5 servings/week)
   • Limit saturated fat and cholesterol

2. Sodium Restriction:

   • Target <2300 mg/day (ideally <1500 mg/day) 6
   • Age-adjusted: 2300 mg for ≤50 years, 1300 mg for 51-70 years, 1200 mg for >70 years 6

3. Weight Management:

   • Target BMI 18.5-24.9 kg/m²
   • Waist circumference: ≤102 cm (men), ≤88 cm (women) 6

4. Physical Activity:

   • 30-60 minutes of moderate aerobic exercise 4-7 days/week 6

5. Alcohol Limitation:

   • Men: ≤14 standard drinks/week
   • Women: ≤9 standard drinks/week 6

6. Smoking Cessation: Mandatory for cardiovascular risk reduction

7. Stress Management: Consider in selected patients 6

Pharmacological Treatment

Treatment Thresholds

Initiate drug therapy based on BP level and cardiovascular risk 6, 1, 2:

• DBP ≥100 mm Hg OR SBP ≥160 mm Hg: Treat regardless of risk factors 6
• DBP ≥90 mm Hg: Treat if target organ damage or cardiovascular risk factors present 6
• SBP ≥140 mm Hg: Treat if target organ damage present 6

Blood Pressure Targets

Standard target: <140/90 mm Hg for most patients 3, 1, 2

Lower targets for specific conditions:

• Diabetes mellitus: <130/80 mm Hg 6, 7, 6
• Chronic kidney disease: <130/80 mm Hg (Note: 2012 Canadian guidelines revised this to <140/90 for non-proteinuric CKD) 6, 8
• Proteinuric CKD (>500 mg/24h or ACR >30 mg/mmol): <130/80 mm Hg 7, 6
• Post-stroke/TIA: <140/90 mm Hg 7

Initial Monotherapy (Uncomplicated Hypertension)

For patients without compelling indications, choose from first-line agents 6, 1, 2:

1. Thiazide diuretics (Grade A—preferred by JNC 7) 1, 2

   • Hydrochlorothiazide 12.5-25 mg daily
   • Chlorthalidone 12.5-25 mg daily (longer-acting, preferred)
   • Avoid hypokalemia (monitor potassium) 6

2. ACE inhibitors (Grade B, not in Black patients as monotherapy) 6

   • Lisinopril 10-40 mg daily
   • Ramipril 2.5-10 mg daily
   • Monitor creatinine and potassium

3. Angiotensin Receptor Blockers (ARBs) (Grade B) 6

   • Losartan 50-100 mg daily
   • Valsartan 80-320 mg daily

4. Long-acting Calcium Channel Blockers (Grade B) 6

   • Amlodipine 5-10 mg daily
   • Nifedipine XL 30-90 mg daily

5. Beta-blockers (Grade B, only for age <60 years) 6

   • NOT recommended as first-line for uncomplicated hypertension in patients ≥60 years 6
   • Metoprolol succinate 50-200 mg daily
   • Atenolol 25-100 mg daily

Combination Therapy

Most patients require ≥2 agents to achieve target BP 1, 2:

Consider initial combination therapy if:

• SBP is 20 mm Hg above target OR
• DBP is 10 mm Hg above target 6, 2
• Caution in elderly or those at risk for hypotension 6

Effective combinations (Grade B-C):

• Thiazide + ACE inhibitor
• Thiazide + ARB
• Calcium channel blocker + ACE inhibitor 6
• Calcium channel blocker + ARB

Avoid:

• ACE inhibitor + ARB combination (Grade A—not recommended) 6
• Non-dihydropyridine CCB + beta-blocker (increased heart block risk) 6

Isolated Systolic Hypertension

Initial therapy 6:

1. Thiazide diuretic (Grade A)
2. Long-acting dihydropyridine CCB (Grade A)
3. ARB (Grade B)

Management of Compelling Indications

Diabetes Mellitus

• Target: <130/80 mm Hg 6
• First-line: ACE inhibitor or ARB (Grade A), especially with:
  • Cardiovascular disease
  • Kidney disease
  • Microalbuminuria (ACR >2.0 mg/mmol men, >2.8 mg/mmol women) 7, 6
• Alternative first-line (without albuminuria): Thiazides or dihydropyridine CCBs (Grade A) 6
• Preferred combination: ACE inhibitor + dihydropyridine CCB over ACE inhibitor + thiazide 6

Chronic Kidney Disease

• Non-proteinuric CKD: Target <140/90 mm Hg 8
• Proteinuric CKD (>500 mg/24h or ACR >30 mg/mmol):
  • Target: <130/80 mm Hg 6
  • First-line: ACE inhibitor (Grade A) 7, 6
  • If ACE inhibitor intolerant: ARB (Grade B) 7, 6
  • Add thiazide diuretic (or loop diuretic if volume overload) 7, 6
  • Avoid ACE inhibitor + ARB combination 6

Coronary Artery Disease

• First-line: ACE inhibitor, ARB, or beta-blocker 6
• Post-MI: Beta-blocker + ACE inhibitor

Cerebrovascular Disease (Post-Stroke/TIA)

• Target: <140/90 mm Hg 7
• Preferred: ACE inhibitor + thiazide diuretic combination (Grade B) 7
• Caution: Avoid precipitous BP drops in acute stroke 7
• Initiate therapy after acute phase

Heart Failure

• ACE inhibitor or ARB
• Beta-blocker (carvedilol, metoprolol succinate, bisoprolol)
• Aldosterone antagonist (spironolactone, eplerenone) for advanced HF 8
• Loop diuretic for volume management

Left Ventricular Hypertrophy

• First-line: ACE inhibitor, ARB, long-acting CCB, or thiazide 6
• Avoid: Direct vasodilators (hydralazine, minoxidil) 6

Renovascular Hypertension

• Treat as uncomplicated hypertension
• Caution with ACE inhibitors/ARBs: Risk of acute renal failure in bilateral disease or solitary kidney 7, 6
• Consider revascularization if:
  • Uncontrolled on ≥3 drugs
  • Deteriorating renal function
  • Bilateral lesions or tight stenosis in solitary kidney
  • Recurrent flash pulmonary edema 7, 6

Resistant Hypertension

Definition: BP remains above target despite adherence to ≥3 antihypertensive drugs (including a diuretic) at optimal doses 3

Approach:

1. Confirm true resistance:

   • Verify medication adherence
   • Rule out white coat effect (use ambulatory/home BP monitoring)
   • Ensure proper BP measurement technique
   • Review for interfering substances (NSAIDs, decongestants, alcohol)

2. Evaluate for secondary causes 6

3. Optimize diuretic therapy:

   • Switch to chlorthalidone if using hydrochlorothiazide
   • Use loop diuretic if GFR <30 mL/min

4. Add fourth agent:

   • Spironolactone 25-50 mg daily (most effective)
   • Alternative: Amiloride, doxazosin, clonidine

Follow-up

• Uncontrolled hypertension: Monthly until target achieved
• Controlled hypertension: Every 3-6 months 6
• Lifestyle modification only: Follow-up within 6 months 6
• Non-hypertensive at last visit: Reassess yearly 6

Improving Adherence

Poor adherence is a major cause of uncontrolled hypertension 3:

• Simplify regimen (once-daily dosing, combination pills)
• Address side effects promptly
• Patient education about asymptomatic nature and long-term risks
• Build trust through empathy 2
• Consider cost and access barriers

Important Caveats

• JNC 2 is obsolete: Current practice follows JNC 7 (2003) or newer guidelines
• Elderly patients: Exercise caution with aggressive BP lowering in frail elderly; individualize targets
• Acute stroke: Do not aggressively lower BP acutely (risk of worsening ischemia) 7, 6
• Pregnancy: Different diagnostic criteria and drug choices apply (not covered by these guidelines)
• African Americans: Higher prevalence, earlier onset, more complications; thiazides and CCBs particularly effective; ACE inhibitors less effective as monotherapy 3, 6, 3